Biotechnology and pharmaceuticals, deemed strategically critical by Commissioner Olivér Várhelyi, face growing global competition with Europe losing ground, especially compared to China which has surged in global clinical trials share over the past decade. Várhelyi's speech to the European Parliament's SANTE-ITRE Committee outlined the Commission's ambitious response: the European Biotech Act, part of a broader health innovation package.
Aiming to Revitalize EU Biotech Industry The Act aims to simplify clinical trial regulatory procedures, reducing authorization times drastically—multicountry trials could see a cut from 106 to 75 days, and single-country trials down from 75 to 47 days. This is intended to make Europe more agile and competitive, aligning with similar or faster timelines than the US or China. Proposals include strengthened coordination among Member States and integrated ethical reviews, while upholding scientific and participant safety standards.
Beyond speeding trials, the Act introduces mechanisms to enhance industrial policy by designating strategic biotech projects eligible for incentives such as an additional year of patent protection via Supplementary Protection Certificates. The Act also supports leveraging health data through the European Health Data Space and promoting AI to enhance development and trial success rates.
Addressing Financing Challenges A notable challenge for EU biotech startups is funding, with the US investing nine times more and most European biotech IPOs occurring in the US market. To address this, the Biotech Act proposes improving the financing environment in Europe, engaging the European Investment Bank Group to channel about €10 billion via the BioTechEU program in the immediate years to bridge funding gaps.
Stakeholder Implications EU biotech and pharmaceutical industries stand to gain from reduced regulatory burdens and incentives, potentially increasing competitiveness. EU regulatory bodies and national authorities face adjustments in coordination and ethical review processes. Patients and healthcare systems could benefit from earlier access to innovative therapies and strengthened prevention approaches. Meanwhile, the financial sector, particularly venture capital and EU public investment institutions, may experience increased roles and responsibilities in biotech financing.
Overall, Várhelyi's proposals indicate a policy direction favoring increasing EU powers in regulatory harmonization and financing facilitation, strengthening innovation ecosystems while balancing patient safety and universal healthcare access. The approach navigates between boosting business competitiveness and maintaining high regulatory standards, reflecting an integrated strategy to regain global leadership in biotechnology.
← Atlas › News